The Current and Future Landscape of PARP Inhibitors for Ovarian Cancer
An expert discusses how clinicians choose between PARP inhibitors for patients with ovarian cancer, and what may be coming next in the field.
Related Articles
Susan Love, a transformative leader in breast cancer movement, dies at 75 She intuitively understood the right thing to do—and then just did it – The Cancer Letter
In May 1991, I sat in a law firm conference room in Washington, DC, listening to a pitch from a small group of women who…
From Whispers to Shouts – MaleBC.org MaleBC.org
From Whispers to Shouts charts public perceptions and the social history of cancer, and the slow but steady advances in cancer care.
From Whispers to Shouts: The Ways We Talk About Cancer
From Whispers to Shouts: The Ways We Talk About Cancer
Cancer and How We Talk About It
Schattner would prefer less use of the more militaristic language around “fighting” cancer, the “war” against cancer.
Cancer and How We Talk About It
Schattner would prefer less use of the more militaristic language around “fighting” cancer, the “war” against cancer.
Mobocertinib Will No Longer Be Available in US for EGFR Exon 20 Insertion+ NSCLC
Takeda has announced that they will be voluntarily withdrawing mobocertinib for patients with EGFR exon 20 insertion mutation-positive non–small cell lung cancer.
From Whispers to Shouts – MaleBC.org MaleBC.org
From Whispers to Shouts charts public perceptions and the social history of cancer, and the slow but steady advances in cancer care.
Elaine Schattner, “From Whispers to Shouts: The Ways We Talk about Cancer” (Columbia UP, 2023)
00:52:17 – The “war on cancer” was launched during the Nixon Administration in 1971, but the term was part of the national dialog on cancer…
Storming the Lab – NYU Journalism
A conversation for journalists, health care providers, and everyone else, featuring Amy Dockser Marcus, Pulitzer Prize-winning author of We the Scientists: How a Daring Team…